Literature DB >> 23765162

Highly efficient selection of epitope specific antibody through competitive yeast display library sorting.

Vinita Puri1, Emily Streaker, Ponraj Prabakaran, Zhongyu Zhu, Dimiter S Dimitrov.   

Abstract

Combinatory antibody library display technologies have been invented and successfully implemented for the selection and engineering of therapeutic antibodies. Precise targeting of important epitopes on the protein of interest is essential for such isolated antibodies to serve as effective modulators of molecular interactions. We developed a strategy to efficiently isolate antibodies against a specific epitope on a target protein from a yeast display antibody library using dengue virus envelope protein domain III as a model target. A domain III mutant protein with a key mutation inside a cross-reactive neutralizing epitope was designed, expressed, and used in the competitive panning of a yeast display naïve antibody library. All the yeast display antibodies that bound to the wild type domain III but not to the mutant were selectively sorted and characterized. Two unique clones were identified and showed cross-reactive binding to envelope protein domain IIIs from different serotypes. Epitope mapping of one of the antibodies confirmed that its epitope overlapped with the intended neutralizing epitope. This novel approach has implications for many areas of research where the isolation of epitope-specific antibodies is desired, such as selecting antibodies against conserved epitope(s) of viral envelope proteins from a library containing high titer, high affinity non-neutralizing antibodies, and targeting unique epitopes on cancer-related proteins.

Entities:  

Keywords:  competitive sorting; dengue virus; epitope specific targeting; human antibody library; yeast display antibody library

Mesh:

Substances:

Year:  2013        PMID: 23765162      PMCID: PMC3906307          DOI: 10.4161/mabs.25211

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  28 in total

Review 1.  New technologies in therapeutic antibody development.

Authors:  O H Brekke; G Å Løset
Journal:  Curr Opin Pharmacol       Date:  2003-10       Impact factor: 5.547

Review 2.  New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.

Authors:  Tadeusz Robak; Ewa Robak
Journal:  BioDrugs       Date:  2011-02-01       Impact factor: 5.807

3.  Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.

Authors:  Shee-Mei Lok; Victor Kostyuchenko; Grant E Nybakken; Heather A Holdaway; Anthony J Battisti; Soila Sukupolvi-Petty; Dagmar Sedlak; Daved H Fremont; Paul R Chipman; John T Roehrig; Michael S Diamond; Richard J Kuhn; Michael G Rossmann
Journal:  Nat Struct Mol Biol       Date:  2008-02-10       Impact factor: 15.369

4.  IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences.

Authors:  Véronique Giudicelli; Xavier Brochet; Marie-Paule Lefranc
Journal:  Cold Spring Harb Protoc       Date:  2011-06-01

5.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

6.  Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.

Authors:  Y L Yip; G Smith; J Koch; S Dübel; R L Ward
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

7.  ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies.

Authors:  Y Kita; J Tseng; T Horan; J Wen; J Philo; D Chang; B Ratzkin; R Pacifici; D Brankow; S Hu; Y Luo; D Wen; T Arakawa; M Nicolson
Journal:  Biochem Biophys Res Commun       Date:  1996-09-04       Impact factor: 3.575

8.  Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus.

Authors:  Gregory D Gromowski; Nicholas D Barrett; Alan D T Barrett
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

9.  Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

Authors:  Gadi Gazit Bornstein; Christophe Quéva; Mohammad Tabrizi; Anne van Abbema; Carlos Chavez; Ping Wang; Orit Foord; Kiran Ahluwalia; Naomi Laing; Sandhya Raja; Shenghua Wen; Larry L Green; Xiaodong Yang; Carl Webster; Ross Stewart; David Blakey
Journal:  Invest New Drugs       Date:  2009-07-21       Impact factor: 3.850

10.  On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes.

Authors:  Ravikumar Rajamanonmani; Celine Nkenfou; Paula Clancy; Yin Hoe Yau; Susana Geifman Shochat; Soila Sukupolvi-Petty; Wouter Schul; Michael S Diamond; Subhash G Vasudevan; Julien Lescar
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

View more
  10 in total

Review 1.  Glioblastoma cancer stem cells: Biomarker and therapeutic advances.

Authors:  Kelli B Pointer; Paul A Clark; Michael Zorniak; Bahauddeen M Alrfaei; John S Kuo
Journal:  Neurochem Int       Date:  2014-03-19       Impact factor: 3.921

Review 2.  Applications of Yeast Surface Display for Protein Engineering.

Authors:  Gerald M Cherf; Jennifer R Cochran
Journal:  Methods Mol Biol       Date:  2015

3.  Guidelines, Strategies, and Principles for the Directed Evolution of Cross-Reactive Antibodies Using Yeast Surface Display Technology.

Authors:  Sara Linciano; Ee Lin Wong; Ylenia Mazzocato; Monica Chinellato; Tiziano Scaravetti; Alberto Caregnato; Veronica Cacco; Zhanna Romanyuk; Alessandro Angelini
Journal:  Methods Mol Biol       Date:  2022

4.  Developing a cell-bound detection system for the screening of oxidase activity using the fluorescent peroxide sensor roGFP2-Orp1.

Authors:  P L Herzog; E Borghi; M W Traxlmayr; C Obinger; H D Sikes; C K Peterbauer
Journal:  Protein Eng Des Sel       Date:  2020-09-14       Impact factor: 1.650

5.  Epitope-specific affinity maturation improved stability of potent protease inhibitory antibodies.

Authors:  Tyler Lopez; Chen Chuan; Aaron Ramirez; Kuan-Hui E Chen; Mary Y Lorenson; Chris Benitez; Zahid Mustafa; Henry Pham; Ramon Sanchez; Ameae M Walker; Xin Ge
Journal:  Biotechnol Bioeng       Date:  2018-09-15       Impact factor: 4.530

6.  Engineered protein-small molecule conjugates empower selective enzyme inhibition.

Authors:  Andrew K Lewis; Abbigael Harthorn; Sadie M Johnson; Roy R Lobb; Benjamin J Hackel
Journal:  Cell Chem Biol       Date:  2021-08-06       Impact factor: 8.116

7.  Combinatorial engineering of N-TIMP2 variants that selectively inhibit MMP9 and MMP14 function in the cell.

Authors:  Valeria Arkadash; Evette S Radisky; Niv Papo
Journal:  Oncotarget       Date:  2018-08-10

8.  Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening.

Authors:  Rama Devudu Puligedda; Rashmi Sharma; Fetweh H Al-Saleem; Diana Kouiavskaia; Arul Balaji Velu; Chandana Devi Kattala; George C Prendergast; David R Lynch; Konstantin Chumakov; Scott K Dessain
Journal:  MAbs       Date:  2019-02-22       Impact factor: 5.857

9.  A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.

Authors:  Dan Hu; Zhongyu Zhu; Shun Li; Yongqiang Deng; Yanling Wu; Nana Zhang; Vinita Puri; Chunyu Wang; Peng Zou; Cheng Lei; Xiaolong Tian; Yulu Wang; Qi Zhao; Wei Li; Ponraj Prabakaran; Yang Feng; Jane Cardosa; Chengfeng Qin; Xiaohui Zhou; Dimiter S Dimitrov; Tianlei Ying
Journal:  PLoS Pathog       Date:  2019-06-26       Impact factor: 6.823

10.  An antibody targeting type III secretion system induces broad protection against Salmonella and Shigella infections.

Authors:  Raphaël Sierocki; Bakhos Jneid; Maria Lucia Orsini Delgado; Marc Plaisance; Bernard Maillère; Hervé Nozach; Stéphanie Simon
Journal:  PLoS Negl Trop Dis       Date:  2021-03-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.